Bilirubin content detection method and kit

Through liquid chromatography-tandem mass spectrometry, the shortcomings of existing bilirubin detection methods in differentiation and quantitative determination are solved, and accurate quantitative detection of various components of bilirubin is achieved. It is suitable for a small number of biological samples and has high accuracy. and high sensitivity.

CN114646717BActive Publication Date: 2024-12-06HUMAN METABOLOMICS INST INC
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202011506061.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2020-12-18
Publication Date
2024-12-06
Estimated Expiration
2040-12-18

AI Technical Summary

Technical Problem

Existing bilirubin detection methods are difficult to accurately distinguish and quantitatively determine free bilirubin and bound bilirubin. In addition, traditional biochemical methods are disturbed by blood lipids and hemolysis, requiring a large number of blood samples, and qualitative quantitative detection cannot be performed in a small number of biological samples.

Method used

Using liquid chromatography-tandem mass spectrometry technology, multi-reaction monitoring mode is set through high performance liquid chromatography, ultra-high performance liquid chromatography or nanoliter liquid chromatography combined with four-stage rod mass spectrometry, time-of-flight mass spectrometry, ion hydrazine mass spectrometry and other technologies. , using an antioxidant stabilizer system, the detection conditions are optimized to quantitatively detect bilirubin and its metabolites.

Benefits of technology

Accurate and rapid qualitative quantitative detection of various components of bilirubin is achieved, overcome the limitations of traditional methods, and is suitable for a small number of biological samples, with high accuracy, low detection limit and high sensitivity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114646717B_ABST
    Figure CN114646717B_ABST
Patent Text Reader

Abstract

The present invention discloses a method for detecting the content of bilirubin. The detection method is a liquid chromatography-tandem mass spectrometry detection method, and the bilirubin content includes the content of any one of free bilirubin, biliverdin, bilirubin monoglucuronide and bilirubin diglucuronide or the content of several of them or their sum. In the liquid chromatography-tandem mass spectrometry detection method, the liquid chromatography is selected from high performance liquid chromatography, ultra-high performance liquid chromatography and nano-liquid chromatography. The content detection method of the present invention can simultaneously or separately perform qualitative and quantitative detection on one or several of the contents of free bilirubin, biliverdin, bilirubin monoglucuronide and bilirubin diglucuronide, and has the characteristics of quick operation, high accuracy and low detection limit compared with traditional biochemical methods.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of analysis and detection, and in particular to a qualitative and quantitative detection and analysis method for bilirubin, which can be applied to the qualitative and quantitative detection of bilirubin in a test sample. Background Art

[0002] Bilirubin is formed by the de-ironization of heme released after the destruction of red blood cells. 80% of bilirubin comes from the spleen and liver, and the rest comes from the bone marrow. Bilirubin exists in three forms: indirect bilirubin or unconjugated bilirubin, conjugated bilirubin, and delta bilirubin. Among them, conjugated bilirubin and delta bilirubin can react directly with diazo reagents and are called direct bilirubin. Direct bilirubin, also known as conjugated bilirubin, is formed by the indirect bilirubin entering the liver and combining with glucuronic acid under the action of glucuronyl transferase in the liver. Bilirubin is an important basis for clinical determination of jaundice and an important indicator of liver function. All types of hepatitis, cirrhosis, and obstructive jaundice can be seen with increased direct bilirubin levels, and it is more sensitive than transaminase. The direct bilirubin content in serum decreases in severe anemia. Therefore, the detection of bilirubin content has very important clinical significance.

[0003] At present, the main biochemical methods for detecting free bilirubin and conjugated bilirubin are: diazonium salt modified JG method, bilirubin oxidase method, chemical oxidation method, vanadic acid method and transcutaneous bilirubin method. Both the diazo method and the oxidase method are easily interfered by blood lipids and hemolysis. At the same time, the traditional biochemical method requires a large amount of blood, and these detection methods have strict requirements on biological samples and can only detect conjugated bilirubin in serum or plasma. Transcutaneous bilirubin meter can only detect total bilirubin, but cannot distinguish between free bilirubin and conjugated bilirubin.

[0004] Chinese patent application CN109991177 A discloses a buffer reagent that can be used for the method of determining the direct bilirubin content by the oxidase method. Chinese patent application CN109541238 A utilizes the reaction of oxidase and its substrate to generate hydrogen peroxide, and then reacts hydrogen peroxide and peroxidase to release oxygen, thereby oxidizing the direct bilirubin in the solution into biliverdin, thereby causing the absorption peak at 450nm to decrease, and the degree of decrease is recorded to calculate the direct bilirubin content. Chinese patent application CN108613976 A discloses a detection kit for a fully automatic biochemical analyzer. Chinese patent application CN111579703 A establishes a qualitative and quantitative method for the three compounds of bilirubin oxidation products BOX A, BOX B and hematinic acid by using a liquid chromatography-tandem triple quadrupole mass spectrometer, and uses standard samples of the three compounds to optimize the instrumental analysis method, including liquid chromatography conditions, mass spectrometry detection conditions and mass spectrometry parameter optimization.

[0005] The above prior art provides quantitative determination of indirect bilirubin and direct bilirubin, but no quantitative determination of the components of direct bilirubin is found. The present invention aims to make up for the deficiencies of the prior art and provide a qualitative and quantitative analysis method of the components in a sample containing bilirubin. Summary of the invention

[0006] The object of the present invention is to provide a quantitative detection method for bilirubin, more specifically, each component of bilirubin, in a test sample containing bilirubin. The object of the present invention is also to provide a kit applicable to the detection method. The object of the present invention is also to provide a device applicable to the detection method. The object of the present invention is also to provide the application of the detection method in the field of medical detection.

[0007] In order to achieve the above invention and creation purpose, the present invention provides a method for detecting bilirubin content in the first aspect, and the detection method is a liquid chromatography-tandem mass spectrometry detection method; the "bilirubin" described in the present invention refers to any one or more of free bilirubin, biliverdin, bilirubin monoglucuronide (bilirubinβ-monoglucuronide, BMG), and bilirubin diglucuronide (bilirubinγ-diglucuronide, BDG) in the test sample. When performing content detection, the aforementioned components can be measured separately or in combination, that is, the bilirubin content can be any one of free bilirubin, biliverdin, bilirubin monoglucuronide and bilirubin diglucuronide, or the content or the sum thereof.

[0008] In some specific embodiments, in the liquid chromatography-tandem mass spectrometry detection method, the liquid chromatography is selected from high performance liquid chromatography, ultra high performance liquid chromatography and nano liquid chromatography.

[0009] In some specific embodiments, the liquid chromatography is selected from high performance liquid chromatography, and the liquid chromatography column is selected from C8 and C18 silica gel packing columns; as an example, the chromatographic column can be selected from Acquity BEH C18 (2.1*50mm, 1.7μm). In some specific embodiments, the column temperature of the chromatographic column is 35-45°C, the injection volume is 1-20μL, and the flow rate is 0.2-0.6ml / min.

[0010] In some specific embodiments, in the liquid chromatography-tandem mass spectrometry detection method, the composition of the mobile phase of the liquid chromatography is: the aqueous phase A is selected from ultrapure water whose pH value is adjusted to 3-4.5 by a pH adjuster; the organic phase B is selected from one or a combination of acetonitrile, ethanol, methanol, propylene glycol, and isopropanol.

[0011] In some specific embodiments, the pH adjuster is selected from ammonium acetate-acetic acid, ammonium formate-formic acid, trifluoroacetic acid and trichloroacetic acid. As a preferred example, the pH adjuster is an ammonium acetate + acetic acid buffer system.

[0012] In some specific embodiments, the organic phase B is selected from one or a combination of acetonitrile, methanol, and isopropanol; as a preferred example, the organic phase B includes acetonitrile, methanol, and isopropanol.

[0013] In some specific embodiments, liquid chromatography uses gradient elution; for exemplary purposes, the following is one of the gradient elution schemes:

[0014]

[0015]

[0016] In some specific embodiments, the mass spectrometry in the liquid chromatography-tandem mass spectrometry detection method is selected from quadrupole mass spectrometry, time-of-flight mass spectrometry, ion hydrazine mass spectrometry and high-resolution orbital hydrazine mass spectrometry; the mass spectrometry conditions and setting of mass spectrometry qualitative and quantitative detection modes include: selecting an electrospray ion source (ESI), selecting an ion scanning mode according to the response of the target compound to be detected; selecting a multiple reaction monitoring method (MRM), and setting multiple reaction monitoring mode parameters.

[0017] In some specific embodiments, a preferred detection sample is provided, characterized in that the detection sample of the detection method is distributed in a system containing a first stabilizer and a second stabilizer.

[0018] The first stabilizer is selected from antioxidants having a certain solubility in non-polar media. The first stabilizer can be selected from one or a combination of butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), propyl gallate (PG), and tert-butylhydroquinone (TBHQ).

[0019] The second stabilizer is selected from antioxidants with a certain solubility in polar media. As a specific embodiment, the second stabilizer is selected from ascorbic acid. As a preferred embodiment, the system containing the first antioxidant and the second antioxidant comprises the first stabilizer butylated hydroxytoluene (BHT) and the second stabilizer ascorbic acid.

[0020] As a specific embodiment, the weight ratio of the first stabilizer and the second stabilizer in the system is in the range of 1:1-1:50, preferably 1:10-1:45, further preferably 1:20-1:40, further preferably 1:30-1:40. In some specific embodiments, the test sample is selected from an organic solvent dispersion system of a biological sample. The organic solvent of the organic solvent dispersion system is selected from methanol, ethanol, acetone, propylene glycol, acetonitrile or a combination of several thereof. The biological sample can be selected from whole blood, plasma, serum and dried blood spots. After the biological sample is dispersed in the organic solvent dispersion system, the supernatant is taken after centrifugation and detected according to the detection method provided by the present invention.

[0021] In some specific embodiments, the biological sample can be processed in the following manner: taurine bilirubin is added to the biological sample as an internal standard, and then an organic solvent dispersion system containing a first stabilizer and a second stabilizer is added, the sample is shaken in the dark, centrifuged, and the supernatant is taken for detection.

[0022] In some specific embodiments, oscillation and centrifugation are performed at 0-10°C, for example, 0°C, 4°C, 10°C can be selected; the shaking conditions are 1000-2000rpm, preferably 1400-1500rpm, the oscillation time is 10-30 minutes, preferably 15-25 minutes; the centrifugal force is 100000-250000g, and the centrifugation time is 10-30 minutes.

[0023] The second aspect of the present invention is to provide a kit for detecting the bilirubin content, characterized in that the detection indicators of the kit include the content of any one of free bilirubin, biliverdin, bilirubin monoglucuronide and bilirubin diglucuronide or the sum of the contents of several of them.

[0024] In some specific embodiments, the kit comprises standards and internal standards for any one or more of free bilirubin, biliverdin, bilirubin monoglucuronide, and bilirubin diglucuronide.

[0025] In some specific embodiments, the internal standard comprises a taurine bilirubin standard.

[0026] In some specific embodiments, the standard of any one or more of free bilirubin, biliverdin, bilirubin monoglucuronide and bilirubin diglucuronide is respectively distributed in a system comprising a first stabilizer and a second stabilizer. In some specific embodiments, the system is selected from a liquid dispersion system containing the standard or a solid system carrying the standard, as a preferred embodiment, such as a test paper.

[0027] In some specific embodiments, the system is an organic solvent dispersion system containing a first stabilizer and a second stabilizer. As a specific example, the organic solvent of the organic solvent dispersion system is selected from one or a combination of methanol, ethanol, acetone, propylene glycol and acetonitrile.

[0028] In other specific embodiments, the system is a solid system, and the solid system includes a solid carrier. The solid carrier is a filter paper selected from analytical filter paper, qualitative analysis filter paper and slow quantitative ashless filter paper. When the filter paper is used as a solid carrier, it is pretreated as follows: soaked in an organic solvent dispersion system containing a first stabilizer and a second stabilizer and then dried in the shade.

[0029] In some specific embodiments, the first stabilizer is selected from antioxidants having a certain solubility in non-polar media. The first stabilizer can be selected from one or a combination of butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), propyl gallate (PG), and tert-butylhydroquinone (TBHQ). The second stabilizer is selected from antioxidants having a certain solubility in polar media. As a specific embodiment, the second stabilizer is selected from ascorbic acid. As a preferred embodiment, the system containing the first antioxidant and the second antioxidant comprises the first stabilizer butylated hydroxytoluene (BHT) and the second stabilizer ascorbic acid. As a specific embodiment, the weight ratio of the first stabilizer and the second stabilizer in the system is in the range of 1:1-1:50, preferably 1:10-1:45, further preferably 1:20-1:40, and further preferably 1:30-1:40.

[0030] The bilirubin content detection method and bilirubin content detection kit provided by the present invention can be used for the quantitative detection of several bilirubins separately or simultaneously, and free bilirubin, biliverdin, bilirubin monoglucuronide and bilirubin diglucuronide for any detection purpose. As an example purpose, it is applied to medical-related diagnosis, risk assessment, etc., and can be used for the diagnosis, risk assessment and drug treatment effect evaluation of any disease or symptom sensitive to these detection indicators or one or more. For example, these diseases or symptoms are selected from neonatal biliary atresia, infantile hepatitis syndrome, cytomegalovirus hepatitis, common bile duct cyst, α1 antitrypsin deficiency disease, Alagille syndrome, cystic fibrosis, total parenteral nutrition-related cholestasis, etc.

[0031] As an exemplary application example, the inventor uses dried blood spots prepared by taking blood from the heel or fingertips of newborns as test samples in the examples. Under the detection conditions of the examples of the present invention, when the content of bilirubin monoglucuronide is greater than 2.5 μM, the subject can be considered to have a high risk of neonatal biliary atresia. As one of the specific implementation methods, the applicant uses the bilirubin monoglucuronide content in the subject's blood sample greater than 2.5 μM as a cutoff value (also called cutoff value) to quickly detect and evaluate the risk of neonatal biliary atresia under the detection conditions described in the examples. The cutoff value in the example is a standard determined under the conditions of the detection method, detection conditions and standard products. According to the enlightenment of the present invention, a person skilled in the art can screen and optimize the quantitative detection method of bilirubin monoglucuronide, including but not limited to high performance liquid chromatography technology, for example, gas chromatography-mass spectrometry detection technology. Under the enlightenment of the present invention, the risk of neonatal biliary atresia can also be evaluated by optimizing the cutoff value based on its detection method and detection conditions. In the screening of the cutoff values ​​of the aforementioned different detection methods, the detection method of the present invention can also be used as a reference and comparison, especially to determine the cutoff values ​​of other detection methods in the absence of clinical samples. Therefore, the risk of neonatal biliary atresia is assessed using the bilirubin monoglucuronide content as a detection index, regardless of the differences in the detection method and cutoff value, should be understood as being within the scope that can be achieved by a general technician in the field under the teaching of the present invention. The technical solution proposed by the present invention can effectively assess the risk of neonatal biliary atresia and can achieve early screening of neonatal biliary atresia in clinical practice. In clinical use, by quantitatively determining the content of biomarkers in neonatal blood samples, newborns with a high risk of biliary atresia can be quickly screened. As a marker for screening of neonatal biliary atresia, the biomarker of the present invention can also be optionally combined with other detection indicators and detection means to further assess the risk of neonatal biliary atresia, and in the diagnosis process, optionally combined with other detection indicators and detection means. Other detection indicators are selected from γ-glutamyl transferase, MMP-7 and clinical indicators.

[0032] The third aspect of the present invention provides a stable bilirubin quantitative detection reagent, characterized in that it comprises a bilirubin standard, wherein the bilirubin standard is distributed in a system containing a first stabilizer and a second stabilizer; the bilirubin includes one or more of free bilirubin, biliverdin, bilirubin monoglucuronide and bilirubin diglucuronide.

[0033] In some specific embodiments, the first stabilizer is selected from antioxidants having a certain solubility in non-polar media. The first stabilizer can be selected from one or a combination of butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), propyl gallate (PG), and tert-butylhydroquinone (TBHQ). The second stabilizer is selected from antioxidants having a certain solubility in polar media. As a specific embodiment, the second stabilizer is selected from ascorbic acid. As a preferred embodiment, the system containing the first antioxidant and the second antioxidant comprises the first stabilizer butylated hydroxytoluene (BHT) and the second stabilizer ascorbic acid.

[0034] As a specific embodiment, the weight ratio of the first stabilizer and the second stabilizer in the system is in the range of 1:1-1:50, preferably 1:10-1:45, more preferably 1:20-1:40, and more preferably 1:30-1:40. In some specific embodiments, the system of the first stabilizer and the second stabilizer is an organic solvent dispersion system containing butylated hydroxytoluene (BHT) and ascorbic acid.

[0035] In some specific embodiments, the organic solvent of the organic solvent dispersion system is selected from one or a combination of methanol, ethanol, acetone, propylene glycol and acetonitrile.

[0036] In some specific embodiments, the system is a solid system, and the solid system includes a solid carrier. As a preferred embodiment, the solid carrier is a filter paper selected from analytical filter paper, qualitative analysis filter paper and slow quantitative ashless filter paper.

[0037] As a specific implementation, when the filter paper is used as a solid carrier, it is preferably pretreated as follows: soaked in an organic solvent dispersion system containing a first stabilizer and a second stabilizer and then dried in the shade.

[0038] The method for preparing any of the above detection reagents comprises distributing a standard substance into the system.

[0039] Use of any of the above-described detection reagents for preparing a kit for detecting bilirubin content.

[0040] The technical solution provided by the present invention realizes the separate or combined quantitative detection of each component of bilirubin. By using a liquid chromatography-tandem mass spectrometer, a qualitative and quantitative method for bilirubin and its metabolites was established. In the study, by optimizing the instrumental analysis method, including liquid chromatography conditions, mass spectrometry detection conditions and mass spectrometry parameter optimization, and sample pretreatment, the target substance can be accurately and quickly qualitatively and quantitatively detected, specifically including selecting liquid phase conditions, setting mass spectrometry conditions, preparing standard solutions, optimizing analysis methods, drawing standard curves, sample pretreatment, and qualitative and quantitative detection of bilirubin and its metabolites in samples.

[0041] The biological samples that can be used in the detection method of the present invention can be plasma, serum, or dried blood spots commonly used in clinical practice. The detection method of the present invention overcomes the limitations of traditional biochemical methods and makes it possible to qualitatively and quantitatively detect bilirubin in a small amount of biological samples.

[0042] The detection method of the present invention can be used to prepare diagnostic products for detecting bilirubin. The "diagnostic products" described in the present invention can be medical devices, test kits, test strips, medical devices, etc. As known to those skilled in the art, the definitions of medical devices, test kits, etc. are related to the provisions of relevant laws, regulations and policies of government authorities, and they have different classification methods and meanings in different countries and regions. The terms such as medical devices, test kits, test strips, etc. described in the present invention are only used to illustrate the application form of the present invention, and are not the meanings defined by government authorities; as long as they are consistent with the purpose of the present invention, the diagnostic products can be medical products registered by relevant government authorities, or they can be products or product combinations used by those skilled in the art in a temporary application manner and form.

[0043] The present invention adopts liquid chromatography-tandem mass spectrometry to quantitatively detect the content of each component of bilirubin, which has the advantages of convenient sampling and reliable detection results. Compared with the traditional biochemical method, it has the characteristics of high accuracy and low detection limit, and can detect free bilirubin, biliverdin, bilirubin monoglucuronide, and bilirubin diglucuronide at the same time, providing more indicators for scientific research, clinical diagnosis and evaluation.

[0044] Compared with the prior art, the detection method of the present invention has the advantages of being simple and rapid, flexible in sample preparation, low in detection limit, good in repeatability and high in sensitivity; and the sample preparation and detection methods are simple and easy, low in cost, and suitable for popularization and use.

[0045] In order to make the purpose, technical solution and effect of the present invention clearer and more specific, the present invention is further described in detail below with reference to the accompanying drawings and through embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0046] Attached Figure 1 This is a liquid chromatogram with ammonium acetate-acetic acid system as mobile phase A. It can be seen from the figure that each target analyte can be effectively separated.

[0047] Attached Figure 2 This is a liquid chromatogram with the ammonium formate-formic acid system as mobile phase A. It can be seen from the figure that the target analytes can be effectively separated.

[0048] Attached Figure 3 This is a liquid chromatogram with trifluoroacetic acid system as mobile phase A. It can be seen from the figure that each target analyte can be effectively separated.

[0049] Attached Figure 4 It is a standard curve prepared based on quality control products.

[0050] Attached Figure 5 The area under the ROC curve for each metabolite in differentiating neonates with biliary atresia from normal neonatal controls.

[0051] Attached Figure 6 Figure 2 is a set of scatter plots showing the differences in bilirubin monoglucuronide levels in samples from newborns with biliary atresia and normal newborns. DETAILED DESCRIPTION

[0052] The main bilirubin in human blood includes four known bilirubin components in serum, namely α, β, γ, and δ bilirubin (bilirubin IXα, Bα; bilirubinβ-monoglucuronide, BMG; bilirubinγ-diglucuronide, BDG; δ-bilirubin, Bδ). Among them, α bilirubin is unconjugated bilirubin (UCB), and β, γ, and δ bilirubin are conjugated bilirubin (CB). Under normal circumstances, there are two main sources of α bilirubin in hepatocytes. One is that it is taken up and transported from peripheral blood into hepatocytes through the organic anion transporting polypeptides (OATP1B1, OATP1B3) transporters on the basement membrane of hepatocytes, and the other is produced by the oxidation and degradation of heme in hepatocytes. 98% to 99% of α-bilirubin in liver cells is converted into β- or γ-bilirubin by glucuronidation of UDP-glucuronosyltransferase 1A1 (UGT1A1), combined with one or two glucuronic acids, and then excreted into the bile duct through the multidrug resistance-associated protein 2 (MRP2) transporter on the bile capillary membrane. In case of cholestasis, especially obstructive cholestasis, the bile secreted by liver cells cannot enter the bile duct normally, thus causing the accumulation and increase of bile acids (BA) and conjugated bilirubin in peripheral blood. Measuring the content of conjugated bilirubin in biological samples of the subject is of great significance for clinical diagnosis.

[0053] At present, the main biochemical methods for detecting free bilirubin and conjugated bilirubin are: diazonium salt modified JG method, bilirubin oxidase method, chemical oxidation method, vanadic acid method and transcutaneous bilirubin method. Both the diazo method and the oxidase method are easily interfered by blood lipids and hemolysis. At the same time, the traditional biochemical method requires a large amount of blood, especially for newborns, the clinical operability is poor. In addition, these detection methods have strict requirements on biological samples and can only detect conjugated bilirubin in serum or plasma. The transcutaneous bilirubin meter can only detect total bilirubin, but cannot distinguish between free bilirubin and conjugated bilirubin.

[0054] The applicant has explored a technical solution for quantitative detection of each component of bilirubin. In the embodiment, the research work includes selecting liquid phase conditions, setting mass spectrometry conditions, preparing standard solutions, optimizing analytical methods, drawing standard curves, sample pretreatment, etc., to achieve qualitative and quantitative detection of each component of bilirubin. The following is an illustration through embodiments.

[0055] The sources of the reagents used in the examples herein are as follows:

[0056] Bilirubin disodium taurate: Product No. 201102, purchased from Sigma-Aldrich China

[0057] Biliverdin: Product No. 30891, purchased from Sigma-Aldrich China

[0058] Free bilirubin: Product No. B4126, purchased from Sigma-Aldrich China

[0059] Methanol: Product No. 900688, purchased from Sigma-Aldrich China

[0060] Acetonitrile: Product No. 900667, purchased from Sigma-Aldrich China

[0061] 2,6-Di-tert-butyl-4-methylphenol (BHT): Product No. B1378, purchased from Sigma-Aldrich China

[0062] Ammonium acetate: Product No. 73594, purchased from Sigma-Aldrich China

[0063] Acetic acid: Product No. 45754, purchased from Sigma-Aldrich China

[0064] Ammonium formate: Product No. 70221, purchased from Sigma-Aldrich China

[0065] Formic acid: Product No. 5330020050, purchased from Sigma-Aldrich China

[0066] Trifluoroacetic acid: Product No. 302031, purchased from Sigma-Aldrich China

[0067] Trichloroacetic acid, product number T6399, purchased from Sigma-Aldrich China

[0068] Bilirubin monoglucuronide, homemade in the applicant's laboratory, CAS No.: 27071-67-6, molecular formula: C39H44N4O12, average molecular weight: 760.786, purity: ≥90%

[0069] Bilirubin diglucuronide, homemade in the applicant's laboratory, CAS No.: 17459-92-6, molecular formula: C45H52N4O18, average molecular weight: 936.921, purity: ≥90%

[0070] Example 1 Establishment and Optimization of Liquid Chromatography-Tandem Mass Spectrometry Method

[0071] In this embodiment, the process of establishing a method for qualitative and quantitative detection of bilirubin components in biological samples based on liquid chromatography-tandem mass spectrometry is described for illustrative purposes, including selecting liquid phase conditions, setting mass spectrometry conditions, preparing standard solutions, optimizing analytical methods, and drawing standard curves.

[0072] The bilirubin sample contains multiple components. The inventors have found through research that when the pH value of the mobile phase A of the liquid chromatography is 3-4.5, the main components of the bilirubin sample, free bilirubin, biliverdin, bilirubin monoglucuronide and bilirubin diglucuronide, can be well separated, and are suitable for a wide range of chromatographic columns, especially C8 and C18 silica gel columns, and have good applicability to column temperature and injection volume.

[0073] The mass spectrometer can select quadrupole mass spectrometer, time-of-flight mass spectrometer, ion hydrazine mass spectrometer and high-resolution orbital hydrazine mass spectrometer; the mass spectrometer conditions and setting of mass spectrometer qualitative and quantitative detection modes include: selecting an electrospray ion source (ESI), selecting an ion scanning mode according to the response of the target compound to be detected; selecting a multiple reaction monitoring method (MRM), and setting multiple reaction monitoring mode parameters.

[0074] 1. Research on testing conditions

[0075] Instruments and reagents: acetonitrile (chromatographic grade), methanol (chromatographic grade), isopropanol (chromatographic grade), ammonium acetate (chromatographic grade), acetic acid (chromatographic grade), manual or automatic pipette (10-200 μL, 100-1000 μL), all were purchased commercially.

[0076] Liquid phase conditions 1: Mobile phase A: ultrapure aqueous solution with ammonium acetate + acetic acid adjusted to pH 3.5, mobile phase B: acetonitrile: methanol: isopropanol = 8:1:1, column temperature: 40°C, chromatographic column: Acquity BEH C18 (2.1*50mm, 1.7μm), injection volume: 5μL.

[0077] Liquid phase condition 2: mobile phase A: ultrapure aqueous solution of ammonium formate + formic acid adjusted to pH 4.5, mobile phase B: acetonitrile: methanol: isopropanol = 8:1:1, column temperature: 40°C, chromatographic column: Acquity BEH C18 (2.1*50mm, 1.7μm), injection volume: 5μL.

[0078] Liquid phase conditions 3: Mobile phase A: ultrapure aqueous solution adjusted to pH 3 with ammonium trifluoroacetate, mobile phase B: acetonitrile: methanol: isopropanol = 8:1:1, column temperature: 40°C, chromatographic column: Acquity BEH C18 (2.1*50mm, 1.7μm), injection volume: 5μL.

[0079] The HPLC procedure is shown in Table 1 below.

[0080] Table 1 HPLC procedures

[0081]

[0082]

[0083] Set the mass spectrometry conditions: As shown in Table 2, select the electrospray ionization source (ESI), select the appropriate ion scanning mode according to the response of the compound, use the multiple reaction monitoring method (MRM) acquisition mode in the positive ion mode, set the multiple reaction monitoring mode parameters; the scanning time is 0.4-4min. Use a semi-automatic injection method to inject the standard solution into the ion source respectively, select the corresponding parent ion peak, perform secondary mass spectrometry analysis on its daughter ion, obtain fragment ion information, and establish the MRM mass spectrometry detection method of the compound.

[0084] Table 2 MRM mass spectrometry parameters for bilirubin and its metabolites

[0085] Serial number Compound Name Precursor ion (m / z) Product ion (m / z) CV CE 1 Free bilirubin 585.3 299.2 50 20 2 Bilirubin monoglucuronide 761.5 299.2 50 40 3 Bilirubin diglucuronide 937.4 299.2 78 50 4 Biliverdin 583.25 297.17 60 34 5 Taurine bilirubin 799.35 406.2 18 46

[0086] In the mass spectrometry analysis process described in the above scheme, the ion source temperature is 150°C, the capillary voltage is 3000 V, the desolvation gas temperature is 500°C, the desolvation gas flow rate is 1000 L / h, and the collision gas is argon.

[0087] Under the above detection conditions, the typical chromatograms of the detection of each component of bilirubin under three different liquid phase conditions are as shown in the attached figure. Figure 1 , Attachment Figure 2 and attached Figure 3shown.

[0088] Preparation of standard solutions

[0089] The above-mentioned liquid phase condition 1 was adopted.

[0090] (1) Preparation of free bilirubin standard solution: Weigh an appropriate amount of free bilirubin and add chloroform to prepare a stock solution with a concentration of 1 mg / mL.

[0091] (2) Preparation of bilirubin monoglucuronide standard solution: Weigh an appropriate amount of bilirubin monoglucuronide and add 50% methanol solution to prepare a stock solution with a concentration of 1 mg / mL.

[0092] (3) Preparation of bilirubin diglucuronide standard solution: Weigh an appropriate amount of bilirubin diglucuronide and add 50% methanol solution to prepare a stock solution with a concentration of 1 mg / mL.

[0093] (4) Preparation of biliverdin standard solution: Weigh an appropriate amount of biliverdin and add methanol to prepare a stock solution with a concentration of 1 mg / mL.

[0094] (5) Mixed standard stock solution: Use methanol containing 1% BHT to prepare a mixed standard containing free bilirubin, bilirubin monoglucuronide, bilirubin diglucuronide and biliverdin at a concentration of 50 μmol / L.

[0095] (6) Mixed standard solution: Dilute the mixed standard stock solution with methanol containing 1% BHT to obtain 20, 4, 1, and 0.2 μmol / L mixed standard solutions in sequence.

[0096] (7) The standard stock solution prepared in the above step was diluted in proportion to prepare a standard solution with the following concentrations. The injection volume was 1 μl. A standard curve was drawn based on the peak area versus the content of the target substance. The standard curve was obtained as follows: Figure 4 shown.

[0097] Example 2 Qualitative and quantitative determination of bilirubin in blood samples

[0098] Sampling: Serum, plasma and whole blood samples were collected from 3 test subjects. Each sample was divided into 3 parts such as serum 01, serum 02, serum 03, etc., for a total of 9 biological samples.

[0099] Biological sample processing:

[0100] Serum 01: Take 20 μl of sample, add 10 μl of taurine bilirubin as internal standard, then add 80 μl of methanol:acetonitrile (volume ratio 1:1) solution containing 1 mg / ml BHT and 200 mmol / L ascorbic acid, shake at 1450 rpm for 20 minutes at 10°C in the dark. Centrifuge at 18000g for 20 minutes at 4°C. Take 60 μl of supernatant into 96-well plate as test sample for HPLC tandem mass spectrometry.

[0101] Serum 02: Take 20 μl of sample, add 10 μl of taurine bilirubin as internal standard, then add 80 μl of methanol:acetonitrile (1:1) solution containing 1 mg / ml BHT and 175 mmol / L ascorbic acid, shake at 1450 rpm for 20 minutes at 10°C in the dark. Centrifuge at 18000 g for 20 minutes at 4°C. Take 60 μl of supernatant into 96-well plate as test sample for HPLC tandem mass spectrometry.

[0102] Serum 03: Take 20 μl of sample, add 10 μl of taurine bilirubin as internal standard, then add 80 μl of methanol:acetonitrile (1:1) solution containing 1 mg / ml BHT and 204 mmol / L ascorbic acid, shake at 1450 rpm for 20 minutes at 10°C in the dark. Centrifuge at 18000 g for 20 minutes at 4°C. Take 60 μl of supernatant into 96-well plate as test sample for HPLC tandem mass spectrometry.

[0103] Plasma 01: Take 20 μl of sample, add 10 μl of taurine bilirubin as internal standard, then add 80 μl of methanol:acetonitrile (1:1) solution containing 1 mg / ml BHT and 180 mmol / L ascorbic acid, shake at 1450 rpm for 20 minutes at 10°C in the dark. Centrifuge at 18000 g for 20 minutes at 4°C. Take 60 μl of supernatant into 96-well plate as test sample for HPLC tandem mass spectrometry.

[0104] Plasma 02: Take 20 μl of sample, add 10 μl of taurine bilirubin as internal standard, then add 80 μl of methanol:acetonitrile (1:1) solution containing 1 mg / ml BHT and 160 mmol / L ascorbic acid, shake at 1450 rpm for 20 minutes at 10°C in the dark. Centrifuge at 18000 g for 20 minutes at 4°C. Take 60 μl of supernatant into 96-well plate as test sample for HPLC tandem mass spectrometry.

[0105] Plasma 03: Take 20 μl of sample, add 10 μl of taurine bilirubin as internal standard, then add 80 μl of methanol:acetonitrile (1:1) solution containing 1 mg / ml BHT and 170 mmol / L ascorbic acid, shake at 1450 rpm for 20 minutes at 10°C in the dark. Centrifuge at 18000 g for 20 minutes at 4°C. Take 60 μl of supernatant into 96-well plate as test sample for HPLC tandem mass spectrometry.

[0106] Whole blood 01: Take 20 μl of sample, add 10 μl of taurine bilirubin as internal standard, then add 80 μl of methanol:acetonitrile (1:1) solution containing 1 mg / ml BHT and 200 mmol / L ascorbic acid, shake at 1450 rpm for 20 minutes at 10℃ in dark. Centrifuge at 18000g for 20 minutes at 4℃. Take 60 μl of supernatant into 96-well plate as test sample for HPLC tandem mass spectrometry.

[0107] Whole blood 02: Take 20 μl of sample, add 10 μl of taurine bilirubin as internal standard, then add 80 μl of methanol:acetonitrile (1:1) solution containing 1 mg / ml BHT and 206 mmol / L ascorbic acid, shake at 1450 rpm for 20 minutes at 10℃ in dark. Centrifuge at 18000g for 20 minutes at 4℃. Take 60 μl of supernatant into 96-well plate as test sample for HPLC tandem mass spectrometry.

[0108] Whole blood 03: Take 20 μl of sample, add 10 μl of taurine bilirubin as internal standard, then add 80 μl of methanol:acetonitrile (1:1) solution containing 1 mg / ml BHT and 190 mmol / L ascorbic acid, shake at 1450 rpm for 20 minutes at 10℃ in dark. Centrifuge at 18000g for 20 minutes at 4℃. Take 60 μl of supernatant into 96-well plate as test sample for HPLC tandem mass spectrometry.

[0109] The treated samples were injected and tested according to the LC-MS / MS conditions in Example 1. Liquid phase condition 1 was selected, and internal standard calibration and external standard method were used for quantification. The test results are shown in Table 3 below.

[0110] Table 3 Measurement indicators and measurement results

[0111]

[0112] Example 3 Qualitative and quantitative determination of bilirubin components in dried blood spots

[0113] Dried blood spot sample preparation

[0114] Dried blood spot samples are prepared by collecting fingertip blood within 4 days after birth. The steps are as follows:

[0115] a) Filter paper pretreatment: Soak 903 filter paper repeatedly in an ethanol solution containing 1 mg / mL BHT and 200 mmol / L ascorbic acid for 2 minutes, take out and drain, then dry the filter paper naturally in the shade for later use.

[0116] b) Preparation: Take a suitable test tube and add an appropriate amount of diluent. Connect a micropipette to a latex tip and check if there is any leakage at the connection. Alternatively, take a disposable micropipette (siphon principle), a blood collection needle, 75% ethanol or iodine, a cotton swab, etc. and keep them ready for use.

[0117] c) Massage: Gently massage the central area of ​​the left ring finger where the ulnar muscles are concentrated, allowing the local tissue to become naturally filled with blood.

[0118] Avoid using the sides or tips of your fingers.

[0119] d) Disinfection: Wipe the blood collection site with 75% ethanol or iodine-containing cotton swab and wait for it to dry naturally.

[0120] e) Acupuncture: Use the thumb, index finger and middle finger of your left hand to fix the blood collection site to keep the skin and subcutaneous tissue taut. Hold a disposable sterilized blood collection needle in your right hand and insert it from the ulnar side of the fingertip to a depth of 2-3mm. Remove the needle immediately.

[0121] f) Wipe blood: After the blood flows out naturally, wipe off the first drop of blood with a sterile dry cotton ball (cotton swab).

[0122] g) Blood aspiration: Use a disposable micropipette to aspirate blood or add blood drops onto filter paper, then use a sterile dry cotton ball (cotton swab)

[0123] Press the wound to stop the bleeding. If the blood does not flow smoothly, use your left hand to apply slight pressure from the distal end of the blood collection site to the fingertips to make the blood flow out.

[0124] h) Label the patient immediately after collecting the sample to avoid confusion.

[0125] i) Dry in a cool place away from light for 4 hours, place in an aluminum foil bag and store at 4°C.

[0126] Dried blood spot sample preparation

[0127] Use a punch sampler to take 3 dried blood spots from the dried blood spots, add 20 μl of pure water, and oscillate with an oscillator at 1450 rpm and 10°C for 20 min. Add 10 μl of internal standard (taurine bilirubin) and 80 μl of methanol:acetonitrile (1:1) solution containing 1 mg / ml BHT and 200 mmol / L ascorbic acid, then continue to oscillate with an oscillator at 1450 rpm and 10°C for 20 min, centrifuge at a centrifugal force of 18000 g and 4°C for 20 min, take 60 μl of supernatant and place it in a 96-well plate for sampling.

[0128] High performance liquid chromatography-tandem mass spectrometry

[0129] The LC-MS / MS conditions in Example 1 were used for sample injection and detection; liquid phase condition 1 was selected, internal standard correction and external standard method were used for quantification, and the measured contents were shown in Table 4 below, and the methodological parameters were shown in Table 5.

[0130] Table 4 Measurement indicators and content measurement results

[0131]

[0132] Table 5 Methodological parameters

[0133]

[0134]

[0135] Example 4 Stable Bilirubin Quantitative Detection Reagent

[0136] The present invention provides a stable bilirubin quantitative detection reagent, comprising a bilirubin standard, wherein the bilirubin standard is distributed in a system containing a first stabilizer and a second stabilizer; the bilirubin includes one or more of free bilirubin, biliverdin, bilirubin monoglucuronide and bilirubin diglucuronide. The purpose of this embodiment is to exemplarily provide a stable bilirubin quantitative detection reagent, and to study its preparation method and stability.

[0137] Preparation of stable bilirubin quantitative detection reagent

[0138] Filter paper pretreatment: The analytical filter paper was repeatedly soaked in an ethanol solution containing 1 mg / mL BHT and 200 mmol / L ascorbic acid for 2 minutes, taken out and drained, then the filter paper was naturally dried in the shade and stored at 4°C.

[0139] Preparation of quantitative detection reagent: Accurately weigh free bilirubin, biliverdin, bilirubin monoglucuronide and bilirubin diglucuronide and dissolve them in ethanol respectively. Use a disposable micropipette to draw up the solution and drop it on the filter paper respectively. Dry it in a cool place away from light for 4 hours, put it in an aluminum foil bag, and store it at 4℃.

[0140] The samples were injected and tested according to the LC-MS / MS conditions in Example 1; liquid phase condition 1 was selected, and internal standard calibration and external standard method were used for quantification. The test results are shown in the following table; quantitative tests were performed on samples that were placed for the following number of days, and the results are shown in Table 6.

[0141] Table 6

[0142]

[0143]

[0144] Example 5: Kit for detecting bilirubin content

[0145] The present invention provides a kit for quantitative detection of bilirubin, wherein the detection index of the kit includes the content of any one of free bilirubin, biliverdin, bilirubin monoglucuronide and bilirubin diglucuronide or the sum thereof. The purpose of this embodiment is to exemplarily provide a bilirubin content detection kit.

[0146] The invention comprises a bilirubin standard product, wherein the bilirubin standard product is distributed in a system containing a first stabilizer and a second stabilizer; the bilirubin comprises one or more of free bilirubin, biliverdin, bilirubin monoglucuronide and bilirubin diglucuronide. The purpose of this embodiment is to exemplarily provide a stable bilirubin quantitative detection reagent, and to study its preparation method and stability.

[0147] The composition of the kit of this example is shown in Table 7.

[0148] Table 7

[0149] name Main Ingredients Quality Control Products Filter paper containing bilirubin standard Internal Standard Taurine Bilirubin Standard Internal standard diluent 2,6-Di-tert-butyl-4-methylphenol in methanol:acetonitrile

[0150] The filter paper containing the bilirubin standard is prepared according to the following method:

[0151] Repeatedly soak the analytical filter paper in an ethanol solution containing 1 mg / mL BHT and 200 mmol / L ascorbic acid for 2 minutes, take it out and drain it, then dry it naturally in the shade and store it at 4°C. Accurately weigh free bilirubin, biliverdin, bilirubin monoglucuronide and bilirubin diglucuronide, respectively, dissolve them in ethanol, use a disposable micropipette to draw the solution and drop it on the filter paper, dry it in a cool place away from light for 4 hours, put it in an aluminum foil bag, and store it at 4°C.

[0152] Example 6 Application of the detection method of the present invention to the screening of biliary atresia in newborns

[0153] The technical solution provided by the present invention makes the quantitative detection method of bilirubin possible. The bilirubin content detection method and bilirubin content detection kit can be used for separately or simultaneously determining several bilirubins, and quantitative detection of free bilirubin, biliverdin, bilirubin monoglucuronide and bilirubin diglucuronide for any detection purpose. It can be applied to medical-related diagnosis, risk assessment, etc., and can be used for diagnosis, risk assessment and drug treatment effect evaluation of any disease or symptom sensitive to these detection indicators or one or more.

[0154] The purpose of this embodiment is to illustrate the use of the technical solution of the present invention in the screening of neonatal biliary atresia; similarly, it can be applied to the screening, diagnosis, risk assessment and monitoring of the effect of therapeutic drugs for other diseases or symptoms that may cause changes in bilirubin composition. For example, these diseases or symptoms are selected from neonatal biliary atresia, infantile hepatitis syndrome, cytomegalovirus hepatitis, common bile duct cyst, α1 antitrypsin deficiency, Alagille syndrome, cystic fibrosis, total parenteral nutrition-related cholestasis, etc.

[0155] This example studies the content of bilirubin and its metabolites in blood samples of normal newborns and newborns with biliary atresia. In this example, blood samples were collected from 39 clinical newborn biliary atresia patients and 300 normal newborn controls, and the blood samples used were dried blood spots prepared within 4 days of birth.

[0156] Dried blood spot sample preparation

[0157] a) Filter paper pretreatment: Soak 903 filter paper repeatedly in an ethanol solution containing 1 mg / mL BHT and 200 mmol / L ascorbic acid for 2 minutes, take out and drain, then dry the filter paper naturally in the shade for later use.

[0158] b) Preparation: Take a suitable test tube and add an appropriate amount of diluent. Connect a micropipette to a latex tip and check if there is any leakage at the connection. Alternatively, take a disposable micropipette (siphon principle), a blood collection needle, 75% ethanol or iodine, a cotton swab, etc. and keep them ready for use.

[0159] c) Massage: Gently massage the central area of ​​the left ring finger where the ulnar muscles are concentrated, allowing the local tissue to become naturally filled with blood.

[0160] Avoid using the sides or tips of your fingers.

[0161] d) Disinfection: Wipe the blood collection site with 75% ethanol or iodine-containing cotton swab and wait for it to dry naturally.

[0162] e) Acupuncture: Use the thumb, index finger and middle finger of your left hand to fix the blood collection site to keep the skin and subcutaneous tissue taut. Hold a disposable sterilized blood collection needle in your right hand and insert it from the ulnar side of the fingertip to a depth of 2-3mm. Remove the needle immediately.

[0163] f) Wipe blood: After the blood flows out naturally, wipe off the first drop of blood with a sterile dry cotton ball (cotton swab).

[0164] g) Blood aspiration: Use a disposable micropipette to aspirate blood or add blood drops onto filter paper, then use a sterile dry cotton ball (cotton swab)

[0165] Press the wound to stop the bleeding. If the blood does not flow smoothly, use your left hand to apply slight pressure from the distal end of the blood collection site to the fingertips to make the blood flow out.

[0166] h) Label the patient immediately after collecting the sample to avoid confusion.

[0167] i) Dry in a cool place away from light for 4 hours, place in an aluminum foil bag and store at 4°C.

[0168] Dried blood spot sample preparation

[0169] Use a punch sampler to take 3 dried blood spots from the dried blood spots, add 20 μl of pure water, and oscillate with an oscillator at 1450 rpm and 10°C for 20 min. Add 10 μl of internal standard (taurine bilirubin) and 80 μl of methanol:acetonitrile (1:1) solution containing 1 mg / ml BHT and 200 mmol / L ascorbic acid, then continue to oscillate with an oscillator at 1450 rpm and 10°C for 20 min, centrifuge at a centrifugal force of 18000 g and 4°C for 20 min, take 60 μl of supernatant and place it in a 96-well plate for sampling.

[0170] High performance liquid chromatography-tandem mass spectrometry

[0171] The samples were injected and tested according to the LC-MS / MS conditions in Example 1; liquid phase condition 1 was selected, and internal standard correction and external standard method were used for quantification. The measurement results showed that in infants with biliary atresia, the mean value of bilirubin monoglucuronide was 28 μmol / L, the maximum value was 82 μmol / L, and the minimum value was 2.9 μmol / L; in normal infants, the mean value of bilirubin monoglucuronide was 1.25 μmol / L, the maximum value was 3.10 μmol / L, and the minimum value was 0.02 μmol / L. Taking bilirubin monoglucuronide as a diagnostic indicator, when the cutoff value was 2.5 μmol / L, the sensitivity of bilirubin monoglucuronide in diagnosing biliary atresia was 100%, and the specificity was 95.2%. Therefore, the upregulation of bilirubin monoglucuronide is expected to serve as a characteristic detection indicator for neonatal biliary atresia, as shown in the attached Figure 5 and attached Figure 6 shown.

[0172] Attached Figure 5 The area under the ROC curve for each metabolite in differentiating neonates with biliary atresia from normal neonatal controls.

[0173] Attached Figure 6 Figure 2 is a set of scatter plots showing the differences in bilirubin monoglucuronide levels in samples from newborns with biliary atresia and normal newborns.

[0174] The above is only a preferred embodiment of the present invention. It should be pointed out that ordinary technicians in this technical field can make several improvements and supplements without departing from the method of the present invention. These improvements and supplements should also be regarded as the scope of protection of the present invention.

Claims

1. A method for detecting bile pigment content, characterized in that: The detection method is a high performance liquid chromatography-tandem mass spectrometry detection method, and the bile pigment content includes the content of free bilirubin, biliverdin, bilirubin monoglucuronide and bilirubin diglucuronide; The detection method comprises dispersing the detection sample in a methanol-acetonitrile dispersion system; The test sample is selected from whole blood, plasma, serum and dried blood spots; The detection method of high performance liquid chromatography-tandem mass spectrometry, wherein the high performance liquid chromatography column is selected from a C18 silica gel packing column, The specification is 2.1*50mm, the particle size is 1.7 microns; the mobile phase of the HPLC is: Mobile phase A: ultrapure aqueous solution adjusted to pH 3.5 by ammonium acetate + acetic acid, mobile phase B: acetonitrile: Methanol:isopropanol=8:1:1; The HPLC gradient elution program was set as follows: The conditions of the tandem mass spectrometry include: the mass spectrometer is operated in positive ion mode, the ion source temperature is 150°C, the capillary voltage is 3000V, the desolvation gas temperature is 500°C, the desolvation gas flow rate is 1000L / h, and the collision gas is argon; the data are collected in multiple reaction monitoring (MRM) mode, and the MRM ion pairs, cone voltage CV and collision energy are as shown in the following table; The scanning time was 0.4-4 min; taurine bilirubin was used as the internal standard.

2. The method for detecting bile pigment content according to claim 1, wherein: The detection sample of the detection method is distributed in a system containing a first stabilizer and a second stabilizer.

3. The method for detecting bile pigment content as claimed in claim 2, characterized in that: The first stabilizer is selected from one or a combination of butylated hydroxyanisole, butylated hydroxytoluene, propyl gallate, and tert-butylhydroquinone.

4. The method for detecting bile pigment content as claimed in claim 2, characterized in that: The second stabilizer is selected from ascorbic acid.

5. The method for detecting bile pigment content as claimed in claim 2, characterized in that: The system containing the first stabilizer and the second stabilizer comprises butylated hydroxytoluene and ascorbic acid.

Citation Information

Patent Citations

  • Direct bilirubin detection kit

    CN108613976A

  • Direct bilirubin assay method and kit

    CN109541238A

  • Stable high-interference-resistance direct bilirubin (oxidase method) detection reagent and detection method

    CN109991177A

  • Method for detecting and analyzing degradation products of bilirubin in biological sample based on LC-MS / MS

    CN111579703A

  • Near-infrared fluorescent protein smURFP and method for directly detecting biliverdin

    CN109932347A